Novel therapies for Dry Eye Syndrome (DES) have been developed based on the research on the role of eye surface temperature-sensitive nerve fibers in tear film regulation.
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.
TRPM8 (transient receptor potential cation channel, subfamily M, member 8) is a novel promising therapeutic target for Dry Eye Syndrome due to its potential combined effect in both signs and symptoms. Clinical candidate formulations has been developed for TRPM8 selective modulator AVX-012.
The origin of AVIZOREX Pharma:
- DES Therapeutics Market Will Grow to $4.6 Billion by 2024, being one of the fastest growing indications in ophthalmology*. Pharmaceutical sales within the DES market were approximately $2.2 Billion in 2o14*.
- Only one prescription drug approved in US (Restasis®, Allergan) with sales near $1 Billion and 1 in Europe (Ikervis®, Santen): Active ingredient in both products is Cyclosporine
- New drugs with effect in both signs and symptoms have blockbuster sales potential